ANOCCA (IEU TI)

signed

The promoter's technologies enable highly precise and efficient analysis of T-cell immunity required to deliver a range of therapeutics and vaccines that specifically harness or manipulate T-cell immunity. With a focus on delivering T-cell receptor modified T-cell therapies (TCR-T) in oncology, the promoter is rapidly progressing a pipeline of novel therapies towards clinical trials utilising its own manufacturing capabilities. The promoter's breakthrough technology has high market potential to address multiple indications and unmet medical needs, well aligned with EU policy priorities. The EIB project will support development of pre-clinical and clinical pipeline of therapeutics, as well as upgrading to Good Manufacturing Practices (GMP) certification the company's own manufacturing unit.